Shadab Mohammed

Ultragenic assisted one of the six leading companies, who were part of a US FDA initiated 2-phase pilot test program to finalize guidelines for submitting pre- and post-marketing individual case safety reports (ICSRs) in E2B R3 format with 28 additional data elements beyond the standard ICH requirements.
||
In July 2023, the US FDA initiated a 2-phase Pilot Test program involving six leading companies to finalize guidelines for submitting pre- and post-marketing Individual Case Safety Reports (ICSRs) in E2B R3 format. This program introduced 28 additional data elements...
continue reading
Ultragenic’s Robotic Process Automation (RPA) implemented at a Pharma Client, delivered rapid ROI with minimal upfront deployment costs.
||
The client is a leading global Contract Research Organization (CRO), providing regulatory, ...
continue reading
Social media & sharing icons powered by UltimatelySocial